Brainstorm Cell Therapeutics I Stock Price, News & Analysis

BrainStorm Cell Therapeutics (NASDAQ: BCLI) appointed Dr. Menghis Bairu to its Board of Directors effective October 28, 2021. Dr. Bairu, a physician and entrepreneur with extensive experience in biotechnology, expressed enthusiasm for contributing to BrainStorm's mission of developing therapies for neurodegenerative diseases. He is the founder and CEO of Proxenia Venture Partners and has held significant roles in various biotech firms, including leading major transactions worth billions. Meanwhile, Sankesh Abbhi will not stand for re-election at the upcoming annual shareholder meeting.

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) announced a conference call scheduled for November 15, 2021, at 8:00 a.m. ET to discuss third-quarter financial results and corporate updates. CEO Chaim Lebovits will lead the call, addressing shareholder inquiries following a financial performance overview. Participants can submit questions until November 14, 2021. The company continues to develop its NurOwn® MSC-NTF cellular therapy platform for neurodegenerative diseases, notably receiving Orphan Drug designation for treating ALS.

BrainStorm Cell Therapeutics (NASDAQ: BCLI) will present its research on MSC-NTF (NurOwn®) exosomes for treating acute lung injury on October 19, 2021, at the NYSCF 2021 Virtual Meeting. The study compares the effectiveness of exosomes from naïve MSCs and those enhanced to secrete regenerative factors. Findings indicate that MSC-NTF exosomes significantly improve oxygen saturation and reduce lung inflammation and fibrosis compared to naïve MSC exosomes. This suggests potential clinical applications for MSC-NTF in lung-related disorders.

BrainStorm Cell Therapeutics (NASDAQ: BCLI) announced findings from a Phase 2 clinical trial of NurOwn® for progressive multiple sclerosis, presented at the 37th ECTRIMS Congress. The trial achieved its primary endpoint, demonstrating safety and tolerability. Key outcomes included reduced neuroinflammatory biomarkers and improved MS functional measures such as walking and cognitive functions. Notably, 38% of treated patients showed significant walking improvement. BrainStorm seeks FDA guidance for future development steps, indicating potential market impact.

BrainStorm Cell Therapeutics (NASDAQ: BCLI) announced the presentation of a scientific abstract regarding its NurOwn Phase 3 clinical trial at the 2021 Northeast Amyotrophic Lateral Sclerosis Consortium conference. The study investigates biomarkers that predict clinical outcomes in ALS patients. Key speakers include Dr. James Berry and executives emphasizing NurOwn's significance in ALS treatment. The company aims to clarify the therapy's mechanisms, supported by positive results across biomarker domains such as neurodegeneration. Detailed findings will be available on BrainStorm's website following the conference.

BrainStorm Cell Therapeutics (NASDAQ: BCLI) announced that Dr. Stacy Lindborg will present at the 2021 Cell & Gene Meeting on the Mesa, scheduled for October 12-14 and October 19-20. The presentation will focus on the expansion of BrainStorm's technology portfolio, emphasizing autologous and allogeneic candidates for neurological diseases, particularly the completed phase 3 trial of NurOwn® for ALS. The webinar will be available on-demand from October 12. The conference will feature numerous presentations on advancements in cell and gene therapy.

BrainStorm Cell Therapeutics (NASDAQ: BCLI) announced the presentation of a scientific abstract on its Phase 2 study of NurOwn® cells for progressive multiple sclerosis at the 37th ECTRIMS Congress. The trial met its primary endpoint of safety and tolerability, with positive results in neurologic function and cognition. The presentation will occur on October 14, 2021, featuring Dr. Jeffrey Cohen from the Cleveland Clinic. CEO Chaim Lebovits and CMO Ralph Kern emphasized the importance of these findings for advancing therapies for progressive MS.

BrainStorm Cell Therapeutics (NASDAQ: BCLI) reported its financial results for the first quarter ended June 30, 2021, indicating a net loss of approximately $6.3 million, down from $7.4 million the previous year. Cash and equivalents totaled around $35.0 million, a decline from $40.0 million as of March 31, 2021. The company successfully received GMP approval for expanded manufacturing capacity in Israel and has strengthened its NurOwn® intellectual property with multiple patents in key markets. Ongoing discussions with ALS experts aim to enhance the regulatory strategy for NurOwn.

BrainStorm Cell Therapeutics (NASDAQ: BCLI) has received GMP approval from the Israel Ministry of Health for three advanced cleanrooms at Sourasky Hospital, doubling its manufacturing capacity for NurOwn®. This expansion is crucial for supplying ALS patients in Israel and Europe, addressing an urgent need for new therapies. The company remains committed to advancing its cellular technology for neurodegenerative diseases, with ongoing discussions on regulatory pathways for NurOwn®.